EPS6.02 Elexacaftor/tezacaftor/ivacaftor results in substantial improvements in chest CT scores in people with cystic fibrosis aged 12 and above over one year of treatment

Abstract

Background: Elexacaftor-Tezacaftor-Ivacaftor (ETI) is associated with improvements in pulmonary function, sweat chloride and nutrition in people with CF (PwCF) and the F508del mutation. As part of RECOVER, a multi-centre post-approval study examining the impact of ETI in PwCF, we sought to establish the impact of one year of ETI on structural lung disease scores by chest CT.